Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan Rogel Cancer Center
With
Damon Runyon Cancer Research Foundation
Age
21–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female gender
Postmenopausal, age 21 or greater
Stage 0-III estrogen receptor and/or progesterone receptor positive breast cancer who will be receiving a standard dose of letrozole, anastrozole, or exemestane
Performance status 0-2
Willing to sign the consent form
You may not be if
Average pain \>=8/10 over the past 24 hours
Peripheral sensory neuropathy grade 2 or higher
Personal history of schizophrenia, or suicidal ideation or attempt within the past 2 years
Thumbnail abnormalities on either hand that are likely to alter pain perception during testing
Clareo Health | Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
